Glaukos price target raised to $145 from $115 at Stephens

1 week ago 7

TipRanks

Sat, January 3, 2026 astatine 6:10 AM CST 1 min read

Stephens raised the firm’s price target connected Glaukos (GKOS) to $145 from $115 and keeps an Overweight standing connected the shares. The firm, which somewhat moderated its outlook for non-iDose U.S. glaucoma revenue, but modestly accrued its iDose gross expectations, views Glaukos arsenic “one of the champion multi-year medtech maturation stories” entering 2026 arsenic iDose is benefiting from expanding reimbursement, deeper utilization, a increasing surgeon base, and a agelong runway of untreated and uncontrolled glaucoma patients.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected GKOS:

Disclaimer & DisclosureReport an Issue

Glaukos terms people raised to $145 from $140 astatine UBS
Glaukos terms people raised to $145 from $120 astatine Truist
Seaport Research healthcare expert holds analyst/industry league call
Glaukos terms people raised to $125 from $113 astatine Citi
Glaukos terms people raised to $125 from $117 astatine Needham

Read Entire Article